IMV Inc. (NASDAQ:IMV) Q3 2019 Earnings Conference Call - Final Transcript
Nov 08, 2019 • 08:00 am ET
Ladies and gentlemen, thank you for standing by, and welcome to the IMV Third Quarter 2019 Update and Earnings Conference Call. At this time all participants are in listen-only mode. After the speakers presentation, there will be a question and answer session. (Operator Instructions) Please be advised that today's conference call is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Pierre Labbe, Chief Financial Officer of IMV. Thank you, and please go ahead, sir.
Thanks, Chris. Good morning, ladies and gentlemen. My name is Pierre Labbe, I'm CFO at IMV. I'm joined today on the call by Fred Ors, our CEO, and we welcome you to our third quarter results and operational update conference call.
Fred will begin with his comments, and I will then carry on with some financial highlights.
Before we begin, I would like to remind you that except for historical information, this audio presentation will contain forward-looking statements, which reflects IMV current expectations about future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause IMV's actual results to differ materially from these statements. These risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly filings and also on our annual information form.
The forward-looking statements made on this call are based on several assumptions which may prove incorrect, and they represent views only as at the date of this call and are presented for the purpose of assisting potential investors in understanding IMV's business and may not be appropriate for other purposes. IMV does not undertake to update forward-looking statements whether written or oral that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV's continuous disclosure documents, including its current annual information form as well as its audited annual consolidated financial statements, which are available on SEDAR at www.sedar.com or on EDGAR at www.sec.gov/edgar.
The press release, the MD&A, and the consolidated financial statements are all posted on our website. And if you wish to receive a copy of either of these documents, please do not hesitate to contact us.
And finally, take note that we will take questions only from sell-side financial analysts. Fred will now start with his comments. Fred?
Thank you, Pierre. Welcome, everybody. At IMV, we are leveraging DPX, our No-Release delivery platform, which enables us to program immune cells in vivo. Importantly, we believe this mechanism of action offers the potential to produce a superior new class of T cell therapy that elicits a more robust and sustained T cell response against cancer when compared to other immunotherapy available on clinical development today.
Our DPX platform is based on the nanoscale particle